Can Caris Life Sciences turn Caris Assure into a broader precision oncology platform?
Caris wants New York access for Caris Assure. The bigger test is whether liquid biopsy scale can satisfy tougher state oversight.
Medical Devices & Diagnostics
Pharma & Biotech
Can Hammes’ Boca Grande project reshape healthcare access on Gasparilla Island?
Island healthcare has a scale problem. Boca Grande Health Clinic’s new facility shows how local care access is being rebuilt closer to patients.
Pharma & Biotech
Mabwell’s 9MW5211 gets FDA clearance, but can a first-in-class autoimmune antibody break through?
Mabwell has FDA clearance for 9MW5211. The bigger test is whether a first-in-class autoimmune antibody can prove durable remission.
Medical Devices & Diagnostics
Why Wenda Pharma’s Phase II data puts BET inhibition back in focus for NUT carcinoma
NUT carcinoma has few options and poor survival. Wenda Pharma’s NHWD-870 may test how fast China can move rare oncology forward.
Medical Devices & Diagnostics
Can Aptar Pharma help solve the bioequivalence challenge in next-generation inhalers?
Greener inhalers need more than lower-carbon chemistry. Aptar Pharma’s FDA-backed work tests the science regulators may need.
Pharma & Biotech
Can Plus Therapeutics Inc. turn REYOBIQ into a differentiated platform for difficult-to-treat CNS cancers?
Can REYOBIQ change CNS cancer treatment? Discover why Plus Therapeutics Inc.’s latest leptomeningeal metastases data is drawing attention.
Pharma & Biotech
Can Artiva Biotherapeutics, Inc. turn deep B-cell depletion into a scalable autoimmune treatment model?
Can AlloNK make autoimmune cell therapy scalable? Explore why Artiva Biotherapeutics, Inc.’s rheumatoid arthritis strategy matters.
Medical Devices & Diagnostics
Why Seek Labs’ amplification chemistry could matter beyond infectious disease testing
Molecular testing is powerful but lab-bound. Seek Labs’ patent raises a sharper question: can point-of-care diagnostics finally scale?
Medical Devices & Diagnostics
Can Reprieve Cardiovascular’s FASTR data change acute heart failure decongestion?
Heart failure care needs faster decongestion without kidney harm. Reprieve’s FASTR data now face the pivotal trial test.
Pharma & Biotech
Merck may have solved the hidden problem behind the oral PCSK9 race
Oral PCSK9 drugs need more than strong LDL data. Merck’s enlicitide paper tests whether peptide manufacturing can scale.